| Thursday, October 9th | |||
|---|---|---|---|
| Hall A | Hall B | ||
| 08:00-08:15 | Welcome Coffee | ||
| 08:15-10:45 | Pre-Meeting Industry-supported Workshop | ||
| 10:45-10:55 | Short Break | ||
| 10:55-11:55 | IACH 1: Opening Plenary | ||
| 11:55-12:25 | Industry-supported MTE Session | ||
| 12:25-12:55 | Lunch Break | ||
| 12:55-14:25 | Transplant 1 | 12:55-14:25 | MPNCo&D 1: Essential Thrombocytosis in 2025: Updates and New Directions |
| Moderators: Claire Harrison, UK; Naveen Pemmaraju, USA; Ruben Mesa, USA | |||
| 12:55-13:05 | Opening Remarks by the MPNCo&D co-Chairs | ||
| 13:05-13:20 | Management of patients with ET in 2025 – state-of-the-art for standard of care: Anna Godfrey, UK |
||
| 13:20-13:35 | Future directions and clinical trial approaches in ET: Claire Harrison, UK |
||
| 13:35-13:50 | What can phylogenetic trees tell us about molecular targets in MPN? TBA | ||
| 13:50-14:05 | AI and spatial modeling in MPNs: current and future directions: Daniel Royston, UK |
||
| 14:05-14:25 | Panel discussion: All session faculty | ||
| 14:25-14:35 | Technical Break | ||
| 14:35-16:05 | Transplant 2 | 14:35-16:05 | MPNCo&D 2: Pre-Fibrotic MF and Myelofibrosis |
| Moderators: Ruben Mesa, USA; Francesco Passamonti, Italy | |||
| 14:35-14:50 | A review of pre-fibrotic MF: updates in 2025: Florian Heidel, Germany |
||
| 14:50-15:05 | State-of-the-art treatment of MF – standard of care options: focus on available JAK inhibitors: Ruben Mesa, USA |
||
| 15:05-15:20 | Anemia in MF – management and treatment options: current and future: Francesco Passamonti, Italy |
||
| 15:20-15:35 | Novel therapies and future clinicial approaches for MF: John Mascarenhas, USA |
||
| 15:35-16:05 | Panel discussion: All session faculty | ||
| 16:05-16:15 | Coffee Break | ||
| 16:15-17:45 | COLYM 1: General Session | 16:15-17:45 | MPNCo&D 3: Polcythemia Vera and CHIP/Inflammation in MPNs |
| Moderators: Stefano Luminari, Italy; Anna Sureda, Spain | Moderators: Mary Frances McMullin, UK; Adam Mead, UK | ||
| 16:15-16:20 | Case report | 16:15-16:30 | PV in 2025: state-of-the-art and standard of care: Adam Mead, UK |
| 16:20-16:30 | Discussion | ||
| 16:30-16:50 | Contribution of genomic to the diagnosis of lymphomas: TBA |
16:30-16:45 | Novel therapies in PV – clinical trials: Susanne Isfort, Germany |
| 16:50-17:10 | Innovation in the prognostic assessment of lymphoma patients: TBA |
16:45-17:00 | Reflections on molecular discoveries in enythrocytosis: Mary Frances McMullin, UK |
| 17:10-17:30 | Infections and lymphomas: lessions for the clinicians: Luca Arcaini, Italy |
17:00-17:15 | Inflammation states in MPN – lessons from MDS: Shahram Kordasti, UK |
| 17:30-17:45 | Panel discussion: All session faculty | 17:15-17:45 | Panel discussion: All session faculty |
| 17:45-19:15 | COLYM 2: Indolent Lymphomas | 17:45-19:15 | IACH 2 |
| Moderators: Stefano Luminari, Italy; TBA | |||
| 17:45-17:50 | Case report | ||
| 17:50-18:00 | Discussion | ||
| 18:00-18:20 | Transformation in indolent lymphomas: identification, prediction and management: Jessica Okosun, UK |
||
| 18:20-18:40 | Follicular lymphomas: impact of novel therapies on the treatment algorithm: TBA |
||
| 18:40-19:00 | Marginal zone lymphomas: current and future approaches to advanced-stage patients: TBA |
||
| 19:00-19:15 | Panel discussion: All session faculty | ||
| 19:15 | Meeting Welcome Reception | ||
| Friday, October 10th | |||
|---|---|---|---|
| Hall A | Hall B | ||
| 08:00-08:15 | Welcome Coffee | ||
| 08:15-09:45 | Transplant 3 | 08:15-09:45 | MPNCo&D 4: Immunotherapy, SCT, Novel Approaches in MPNs |
| Moderators: Anna Godfrey, UK; Susanne Isfort, Germany | |||
| 08:15-08:30 | Novel clinical approaches targeting CALR – translational/clinical approaches: Bethan Psaila, UK |
||
| 08:30-09:00 | Should blastic phase MPN be aggressively treated? Yes: Tania Jain, USA No: Bart Scott, USA |
||
| 09:00-09:15 | Recent data to achieve the best from allografting in MF: Donal McLornan, UK |
||
| 09:15-09:45 | Panel discussion: All session faculty | ||
| 09:45-10:00 | Coffee Break | ||
| 10:00-11:30 | Industry-supported Morning Symposium | 10:00-11:30 | CME Morning Symposium |
| 11:30-11:40 | Technical Break | ||
| 11:40-13:10 | Transplant 4 | 11:40-13:10 | MPNCo&D 5: Spotlight on Rare MPNs: Not as Rare As You Think |
| Moderators: Deepti Radia, UK; TBA | |||
| 11:40-11:55 | CMML – updates and future directions: TBA |
||
| 11:55-12:10 | Hypereosinophilic syndromes in 2025: TBA |
||
| 12:10-12:25 | Systemic mastocytosis: Deepti Radia, UK |
||
| 12:25-12:40 | Focus on rare hematologic malignancies: pearls and reflections: Naveen Pemmaraju, USA |
||
| 12:40-13:10 | Panel discussion: All session faculty | ||
| 13:10-13:40 | Lunch Break | ||
| 13:40-15:10 | Industry-supported Lunch Symposium | 13:40-15:10 | Industry-supported Lunch Symposium |
| 15:10-15:20 | Technical Break | ||
| 15:20-16:50 | COLYM 3: Chronic Lymphocytic Leukemia | 15:20-16:50 | COMydAL 1: MDS I |
| Moderators: Mohamed Kharfan-Dabaja, USA; Stefano Luminari, Italy | Moderators: TBA | ||
| 15:20-15:25 | Case report | 15:20-15:35 | An update on IDH inhibitors in MDS: Lionel Adès, France |
| 15:25-15:35 | Discussion | ||
| 15:35-15:55 | Time-limited vs continuous therapy as front-line treatment of CLL: matching the bset approach to the right patient: Talha Munir, UK |
15:35-15:50 | An update on AZA-based combinations in MDS: TBA |
| 15:55-16:15 | Treatment of relapsed and/or refractory CLL after failure of a covalent BTK and BCL2 inhibitors: Farrukh Awan, USA |
15:50-16:05 | An update on immune biomarkers and targeting in MDS: Shahram Kordasti, UK |
| 16:15-16:35 | BTK degraders: what are they and how will they shape CLL management? TBA |
16:05-16:20 | An update on response and MRD assessment in MDS: Arjan van Loosdrecht, Netherlands |
| 16:35-16:50 | Panel discussion: All session faculty | 16:20-16:50 | Panel discussion: All session faculty |
| 16:50-17:00 | Coffee Break | ||
| 17:00-18:30 | COLYM 4: Hodgkin Lymphoma | 17:00-18:30 | COMydAL 2: AML I |
| Moderators: Anna Sureda, Spain; TBA | Moderators: TBA | ||
| 17:00-17:05 | Case report | 17:00-17:15 | Should FLT3 inhibitors be a frontline thearpy for older FLT3-mut AML? TBA |
| 17:05-17:15 | Discussion | ||
| 17:15-17:35 | Divide across the pond: how to select between N-AVD or BrECADD in newly diagnosed cHL? TBA |
17:15-17:30 | AZA-VEN vs AZA-IVO for frontline therapy of older IDH1 mutated AML? Ume Borate, USA |
| 17:35-17:55 | Salvage N-AVD failures: is it a hacksaw ridge? | 17:30-17:45 | How should we stratify AML in 2025? TBA |
| 17:55-18:15 | Do all relapsed cHL need an autologous treatment as consolidation? TBA |
17:45-18:00 | An update on menin inhibitors in AML patients: Amer Zeidan, USA |
| 18:15-18:30 | Panel discussion: All session faculty | 18:00-18:30 | Panel discussion: All session faculty |
| 18:30-19:00 | IACH 3: Awards | ||
| Saturday, October 11th | |||
|---|---|---|---|
| Hall A | Hall B | ||
| 08:00-08:15 | Welcome Coffee | ||
| 08:15-09:45 | Transplant 5 | 08:15-09:45 | IACH 4 |
| 09:45-10:00 | Coffee Break | ||
| 10:00-11:30 | COLYM 5: Aggressive B-Cell Lymphoma | 10:00-11:30 | COMydAL 3: MDS/MPN |
| Moderators: Anna Sureda, Spain; Mohamed Kharfan-Dabaja, USA | Moderators: Lisa Pleyer, Austria & TBA | ||
| 10:00-10:05 | Case report | 10:00-10:15 | Defining MDS/MPN entities for clinical decision making: Daniel Wiseman, UK |
| 10:05-10:15 | Discussion | ||
| 10:15-10:35 | “All comers” vs “molecularly driven” treatment strategies in first-line DLBCL patients: where are we heading to? TBA |
10:15-10:30 | Molecular classification along the myeloid neoplasm spectrum: Matteo Della Porta, Italy |
| 10:35-10:55 | Changing the field in RR DLBCL: CAR-T cells and BiEsp MoAb: TBA |
10:30-10:45 | CMML molecular landscape: Laura Palomo, Spain |
| 10:55-11:15 | Is there life after CAR-T? Mechanisms of resistance and potential therapeutic strategies: Roni Shouval, USA |
10:45-11:00 | MDS/MPN – an update on therapeutics: TBA |
| 11:15-11:30 | Panel discussion: All session faculty | 11:00-11:30 | Panel discussion: All session faculty |
| 11:30-13:00 | COLYM 6: Mantle Cell Lymphoma | 11:30-13:00 | COMydAL 4: MDS II |
| Moderators: Anna Sureda, Spain; TBA | Moderators: Sophie Park, France & TBA | ||
| 11:30-11:35 | Case report | 11:30-11:45 | Dissecting biology of MDS Del5q: Julia Montoro, Spain |
| 11:35-11:45 | Discussion | ||
| 11:45-12:05 | Should we abandon auto-HCT as first-line consolidation therapy in de novo MCL patients? TBA |
11:45-12:00 | Should we improve selection of patients for ESA therapy? Marco Raddi, Italy |
| 12:05-12:25 | Choosing between a BTK inhibitor and CAR-T cell therapy in RR MCL: TBA |
12:00-12:15 | Autoimmunity in MDS: Lin Pierre Zhao, France |
| 12:25-12:45 | Management of relapsed TP53 mutated mantle cell lymphoma: is allogeneic HCT still a major player? TBA |
12:15-12:30 | Evolving therapeutic algorithm for LR MDS: ESA, luspatercept, imetelstat: Valeria Santini, Italy |
| 12:45-13:00 | Panel discussion: All session faculty | 12:30-13:00 | Panel discussion: All session faculty |
| 13:00-13:30 | Lunch Break | ||
| 13:30-15:00 | Industry-supported Lunch Symposium | 13:30-15:00 | Industry-supported Lunch Symposium |
| 15:00-15:10 | Technical Break | ||
| 15:10-16:40 | IACH 5 | 15:10-16:40 | COMydAL 5: AML II |
| Moderators: TBA | |||
| 15:10-15:25 | Are retinoids out of fasion in non-APL AML/HR-MDS? Amy deZern, USA |
||
| 15:25-15:40 | An update on TP53 AML biology and targeting in AML/HR-MDS: Max Stahl, Germany |
||
| 15:40-15:55 | Germline predisposition in AML and MDS: Marie Sebert, France |
||
| 15:55-16:10 | The role of inflammation in AML and MDS: Antonio Curti, Italy |
||
| 16:10-16:40 | Panel discussion: All session faculty | ||
| 16:40-16:45 | Closing Remarks | ||